Diabetes mellitus ve komplikasyonlarının tanı,tedavi ve izlem ...

83. Rodbard HW, Blonde L, Braithwaite SS, et al. AACE Diabetes Mellitus Clinical Practice Guidelines
Task Force 2007. American Association of Clinical Endocrinologists Medical Guidelines for Clinical
Practice for the Management of Diabetes Mellitus. Endocrine Practice 2007;13 (Suppl 1):1-66.
84. Rosenzweig JL, Ferrannini E, Grundy SM, et al. The Endocrine Society’s Clinical Practice Guidelines.
Primary prevention of cardiovascular disease and type 2 diabetes in patients at risk. J Clin Endocrinol
Metab 2008;93:3671-89.
85. Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycated hemoglobin and microvascular
complications: is there a natural cut-off point for the diagnosis of diabetes. Diabetologia. 22 April
2009 [Epub ahead of print].
86. Satman İ (Editör). Diabetes Mellitus Özel Sayısı. Türkiye Klinikleri Endokrinoloji 2003;1:157-68.
87. Satman İ, İmamoğlu Ş, Yılmaz C ve TEMD Diabetes Mellitus Çalışma Grubu. Diabetes Mellitus ve
Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu-2008. 3. Baskı, Müka Matbaa Reklamcılık Yayıncılık
Ltd. Şti., İstanbul, Eylül-2008, s.1-144.
88. Sinclair AJ, Finucane P (Editors). Diabetes in Old Age. Second Edition. Jonh Wiley & Sons, Chichester,
1995.
89. Skyler J, Bergenstal R, Bonow R, et al. Intensive glycemic control and the prevention of cardiovascular
events: implications of the ACCORD, ADVANCE, and the VA diabetes trials. Diabetes Care 2009;32:187-
92.
90. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for treatment of diabetic ulcers. Wound Rep Reg
2006;16:680-92.
91. Stolar MW, Hoogwerf BJ, Boyle PJ, Gorshow SM, Wales DO. Managing type 2 diabetes: going beyond
glycemic control. J Managed Care Pharmacy 2008;14(Suppl S-b): S2-19.
92. Technology Appraisal Guidance No. 57, Issue date February 2003, Review date February 2006 ISBN:
1-84257-269-5 N0195 70k 1P Feb 03 (ABA).
93. TEMD Diabetes Mellitus Çalışma Grubu. Diabetes Mellitus Tanı, İzlem ve Tedavi Kılavuzu. Türkiye
Endokrinoloji ve Metabolizma Derneği, 2006.
94. The AACE/ADA Task Force on Inpatient Diabetes. American Diabetes Association consensus statement
on inpatient diabetes and glycemic control: A call to action. Diabetes Care 2006;29:1955-62.
95. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): 1. Prevalence of
hypertension in newly presenting type 2 diabetic patients and the association with risk factors for
cardiovascular and diabetic complications. J Hypertens 1993;11:309-17.
96. The International Expert Committee. International Expert Committee Report on the role of the A1C
assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
97. The International Expert Committee. International Expert Committee Report on the role of the A1C
assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
98. The Practical Guide on Identification, Evaluation and Treatment of Overweight and Obesity in Adults.
NIH Publications, 2000.
99. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). National Cholesterol Education Program. JAMA, 2001;285:2486-
97.
100. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects
(XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention
of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61. Erratum in: Diabetes Care
2004;27:856.
101. Tüzün M, Çetinkalp Ş (Editörler). Diabetes Mellitus Cep ve El Kılavuzu. Asya Tıp Kitapevi, İzmir, 2004.
102. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on
complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU | 175